CTI BioPharma Corp. (Nasdaq: CTIC) has recently made headlines with the announcement of a significant development. The company has entered into a definitive agreement with Swedish Orphan Biovitrum AB, which will acquire CTI in an all-cash transaction. Under the terms of the agreement, each share of CTI's common stock will be purchased for $9.10. This news has sparked interest in the market, and as a result, CTIC's pre-market trading shows a positive trend. As of now, CTIC is trading at $8.91, experiencing a notable increase of $4.09 (84.85%).

In another noteworthy update, Addex Therapeutics Ltd (Nasdaq: ADXN) has shared positive news regarding their ADX71149 (JNJ-40411813) Phase 2 epilepsy clinical study. An Independent Interim Review Committee (IRC) has recommended the continuation of the study after reviewing unblinded data from Part 1 of patient Cohort 1. Janssen Pharmaceuticals, Inc. is conducting the clinical study, and Addex stands to benefit significantly from this collaboration. As part of their agreement, Addex is eligible for success-based development and regulatory milestone payments totaling up to €109 million, in addition to low double-digit royalties on net sales of compounds developed under the partnership.

The market has responded positively to this news, as evidenced by the pre-market trading figures for ADXN. Currently, ADXN is trading at $1.04, experiencing a notable increase of $0.29 (39.24%) in pre-market activity. 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)